Download Brochure - Cancer Epidemiology Research Programme

Cancer Epidemiology Research Programme
ABOUT US
T
he Catalan Institute of Oncology (ICO) is a public research institute that
takes a comprehensive approach towards cancer treatment by focussing
on prevention, patient care, specialist training and research. With more than
1000 permanent and temporary staff, ICO’s organisational structure is based
on a multicentre, regional model that includes a network of monographic cancer
centres–located in Barcelona (L’Hospitalet and Badalona), Girona and Tarragona, as
well as several teaching and general hospitals, and research institutes, including the
University Hospital of Bellvitge and the Institute of Biomedical Research (IDIBELL).
ICO’s mission is to reduce the impact of cancer in Catalonia by bringing the ‘specialist’
to the patient and to ensure the provision of the highest quality health care possible.
T
he Cancer Epidemiology Research Programme (PREC) at ICO is devoted
to research on the causes, epidemiology, early diagnosis and prevention of
cancer. PREC provides advice on the design, development and assessment
of cancer prevention strategies, such as providing assessments of
population-based cancer screening programmes, and providing estimates of costeffectiveness of health promotion programming and cancer prevention measures.
With demonstrated expertise in the areas of laboratory, clinical and population-based
methods, PREC has become internationally recognised for conducting high quality
research, while its scientists have made cutting-edge discoveries and noteworthy
contributions to the field of cancer epidemiology. PREC is composed of two units:
Infections and Cancer and Nutrition and Cancer.
F. Xavier Bosch
Silvia de Sanjosé
Administration
& Management
IT
Cristina Rajo
Jesús Muñoz
F. Xavier Bosch
Monographs &
PVR Journal
F. Xavier Bosch
Courses & Projects
Assumpta Company
INCA
UNIC
UNAC
Xavier Castellsagué
Antoni Agudo
Miguel Angel Pavón
Genotyping
HPV Information
Centre
PREDICOP
Laia Bruni
Antoni Agudo, Genevieve Buckland, Noemie Travier
Molecular
Epidemiology
Gastric Cancer
Miguel Angel Pavón
Screening and
Quality Assurance
Laia Alemany
Carlos A González, Núria Sala, Antoni Agudo
Montserrat Torres
Modelling
Quality Control
Mireia Diaz
Pancreatic Cancer
Eric J Duell
Ana Estaban
Vaccines
EPIC-Europe
Xavier Castellsagué, F. Xavier Bosch, Maria Brotons
Inflammation
Antoni Agudo, Paula Jakszyn
Screening
Iron
Silvia de Sanjosé
Paula Jakszyn
Acrylamide
Haematoncology
Eric J Duell
Silvia de Sanjosé, Delphine Casabonne, Laura Costa
Polyphenols
Raul Zamora
INFECTIONS AND CANCER UNIT (UNIC)
U
NIC places a special emphasis on the accumulation of
aetiological knowledge regarding exposure and genetic
susceptibility of cancer, and its application to primary
prevention. Much of UNIC’s research utilises molecular
epidemiology to determine the underlying molecular mechanisms
associated with the viral origins of cancer. With collaborations in
more than 60 countries, the unit has become a leading authority in
the field of viral infections and cancer—with HPV-related research
receiving high-priority for the last twenty years.
Contact Information:
Infections and Cancer Unit (UNIC)
Head of Unit: Xavier Castellsagué
Email: [email protected]
Phone: +34 932 607 812
Website: http://icoepi.net/infections-and-cancer-unit/
HPV-RELATED RESEARCH
INFECTIONS AND CANCER LABORATORY (INCA-LAB)
P
REC’s Infections and Cancer Laboratory (INCA-LAB) is composed of a
multidisciplinary team of biologists, virologists, technicians, PhD students
and post-docs. The INCA-LAB conducts research focusing on the molecular
epidemiology of HPV by supporting national and international epidemiological
studies. The techniques applied in the laboratory include commercial and in-house
PCR-genotyping in different formats, as well as studies of variants. The INCALAB also conducts validation studies of new technologies for possible application
in the field of research and clinical investigation. The INCA-LAB is recognised as
a reference laboratory for HPV screening in Catalonia. The lab heads up quality
control of HPV performance assays (e.g., inter- and intra-laboratory assessment) as
part of the cervical cancer screening activities in Catalonia. In addition, the INCALAB performs detection and genotyping of HPV-DNA as part of the clinical diagnosis
process.
Contact Information:
Infections and Cancer Laboratory (INCA-LAB)
Head of Laboratory: Miguel Angel Pavón
Email: [email protected]
Phone: +34 932 607 812
Website: http://www.idibell.cat/modul/infections-and-cancer-laboratory/en
MOLECULAR EPIDEMIOLOGY
T
he Retrospective International Survey of HPV Time Trends
Cervical Cancer (RIS HPV TT) and The International Survey
on HPV Prevalence and Type Distribution in Vulvar, Vaginal,
Anal, Penile and Oropharyngeal Neoplasias (HPV VVAPO).
One of the unit’s primary lines of research includes the study of HPVDNA prevalence and genotype distribution in preneoplastic lesions
and cancers of the vulva, vagina, anus, penis, head and neck (namely
the RIS HPV TT and the HPV VVAPO studies). The main objectives
of these two studies are to: 1) obtain robust prevalence estimates of
HPV-attributed preneoplastic lesions and cancer in these anatomical
sites, and 2) report the global type distribution of HPV according to
geographical area, age and year of diagnosis. The studies involve
the participation of more than 90 centres in 45 countries. At present,
more than 15 000 samples of cancerous tissue have been collected,
preserved in paraffin and analysed. Principal results are now available
online and in print.
PI: Laia Alemany
Key Publication: Alemany L, et al. HPV DNA prevalence
and type distribution in anal carcinomas worldwide. Int
J Cancer, 2015 Jan 1; 136 (1):98-107. doi: 10.1002/
ijc.28963. Epub 2014 May 30. IF: 5,007; Q1; PMID:
24817381
HPV INFORMATION
D
issemination of information on HPV and cancer. UNIC has developed and
maintains the ICO/IARC Information Centre on HPV and Cancer. The ICO/IARC
HPV Information Centre is a web-based resource designed to compile, edit and
disseminate scientific data on HPV and HPV-related cancers. The Centre’s mission
is to ‘accelerate the development and introduction of HPV prevention strategies to reduce the
incidence of cervical cancer and other HPV-related diseases worldwide.’ The Centre provides
data and information regarding HPV prevalence and type distribution, HPV-related cancers,
vaccination, screening and prevention. In 2006, the centre launched a series of international
reviews published as scientific monographs and regional reports. To supplement these initial
reviews, an international compilation of HPV and cervical cancer statistics for every country in
the world was released in 2007. In 2008, the project published three volumes, which provided
an updated overview of progress in the research field, an expanded understanding of the
infection and disease spectrum, and gave information on the technical developments for the
prevention of HPV-related diseases. The centre is now preparing the latest update of the
general chapters describing scientific advances in the field. For more information, please visit:
www.hpvcentre.net.
Co-Directors: Xavier Castellsagué and F. Xavier Bosch
Key Publication: Bosch FX, et al. Comprehensive Control of HPV Infections and Related
Diseases Vaccine, Volume 30, Supplement 5, 2012.
SCREENING
C
ervical cancer screening in Catalonia and beyond.
UNIC has taken the lead in cervical cancer
screening in Catalonia by spearheading the
evaluation of screening activities and reviewing
government recommendations. The unit was involved in
writing the 2006 and 2015 screening recommendations for
the Health Department of the Catalan Government and they
continue to work towards the introduction of HPV testing
in primary screening as a useful tool in the detection of
persistent infection among women at-risk of cervical cancer.
PI: Silvia de Sanjosé
Key Publication: de Sanjosé et al. Screening of cervical
cancer in Catalonia 2006-2012. Ecancermedicalscience
2015 29;9:532. Epub 2015 Apr 29.
HPV VACCINE TRIALS
E
valuating the impact of HPV vaccination programmes. Prophylactic HPV
vaccination is a powerful tool for primary prevention of cervical cancer and
other HPV-related diseases. Since 2003, the group has been actively involved
in seven Phase III trials evaluating the safety, immunogenicity and efficacy
of the bivalent, quadrivalent and nonavalent prophylactic vaccines as well as a trial
testing a therapeutic HPV vaccine. In addition, UNIC is carrying out Phase IV studies to
assess the impact of the Catalan HPV Immunization Programme on the future burden
of HPV-related diseases, including genital warts and cervical pre-cancers in Catalonia.
Finally, the unit is also leading the FASTER project, a multinational study to assess
novel preventative strategies combining HPV vaccination and HPV-based screening in
adult women for a rapid and faster reduction of cervical cancer in Europe.
PI: Xavier Castellsagué
Key Publication: Bosch FX, et al. HPV-FASTER: broadening the scope for prevention of
HPV-related cancer. Nat Rev Clin Oncol, 2015 Sep 1. doi: 10.1038/nrclinonc.2015.146.
MODELLING
M
odelling and economic evaluation of cancer
prevention measures. UNIC uses methods
from decision science to address public health
problems by developing and utilising a variety of
mathematical models to perform cost-effectiveness studies
in collaboration with Harvard University’s Center for Health
Decisions Science (CHDS). Different analyses have been
conducted that evaluate the risks, benefits and costs of
various cervical cancer prevention strategies, including
HPV vaccination and screening to inform health decisionmaking. UNIC has also used models to evaluate the impact
of vaccination and screening in Spain, and has worked in
collaboration on models for Asia, Latin-America, Africa and
Europe.
PI: Mirera Diaz
Key Publication: Diaz M, et al. Cost-effectiveness of
human papillomavirus vaccination and screening in Spain.
Eur J Cancer. 2010 Nov;46(16):2973-85. doi: 10.1016/j.
ejca.2010.06.016. Epub 2010 Jul 16. PubMed PMID:
20638840.
OTHER ACTIVITIES
EPILYMPH
L
aunched in 1998, EpiLymph is a multidisciplinary group of epidemiologists, haematologists and statisticians that evaluates the
role of infectious, environmental and genetic factors in the aetiology of lymphomas. The EpiLymph group is involved in several
consortia: the International Lymphoma Epidemiology Consortium (INTERLYMPH), the EPIC Lymphoma Working Group and the
International Cancer Genome Consortium on Chronic Lymphocytic Leukemia (CLL)—working together in the epidemiological
investigation of lymphoma worldwide. The group is currently leading the study on CLL in the MCC-Spain study examining the etiologic
and prognostic factors of this disease.
Co-PIs: Silvia de Sanjosé and Delphine Casabonne
Key Publication: Nieters A, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.
Gastroenterology. 2006 Dec;131(6):1879-86. Epub 2006 Sep 20. PubMed PMID: 17087949.
O
perational since 2004, e-oncología is the first programme of its kind to offer specialised cancer training in Spanish. The web-based, e-learning platform represents a strategic alliance
between the Catalan Institute of Oncology (ICO), the Spanish Society of Medical Oncology
(SEOM), the International Federation of Gynecology and Obstetrics (FIGO), the International
Atomic Energy Agency (IAEA) and the International Agency for Research on Cancer (IARC), among
others. The programme strives to expand the boundaries of traditional training and generate knowledge
networks among specialists, teachers and all professionals interested in oncology.
The programme offers:
•
•
•
•
•
More than 200 professionals working as authors / tutors or course directors
Courses in 8 languages, including Spanish, English, French, Russian and Portuguese
An international, collaborative network that supports e-oncology
An adaptable curriculum with courses tailored to the specific needs of each country and region
International and national CME course accreditation
To date, more than 17 000 individuals have participated in the programme and more than 2 300 hours of
virtual teaching have been completed.
Programme Director: F. Xavier Bosch
Website: www.e-oncologia.org
NUTRITION AND CANCER UNIT (UNAC)
C
omprised of a multidisciplinary group of epidemiologists,
nutrition specialists, molecular biologists, geneticists,
and statisticians, much of UNAC’s focus is conducting
aetiological research on the relationship between
nutrition and cancer. This includes mainly research on diet and
dietary pattern, body composition and physical activity as possible
determinants of cancer. UNAC’s interests also include the role of
environmental factors as well as genetic susceptibility in human
carcinogenesis. To achieve this, UNAC aims to combine traditional
epidemiologic approaches with innovative tools, including the
use of biomarkers of exposure and susceptibility. The unit is also
developing new lines of research on the role of nutritional factors
in disease prognosis and progression among cancer survivors.
Most of UNAC’s research is carried out within the framework of the
European Prospective Investigation on Diet, Cancer and Health
(EPIC), in collaboration with the European Union, IARC/WHO and
the Imperial College London.
Contact Information:
Nutrition and Cancer Unit (UNAC)
Head of Unit: Antonio Agudo
Email: [email protected]
Phone: +34 932 607 812
Website: http://icoepi.net/nutrition-andcancer-unit/
EPIC-RELATED RESEARCH
EUROPEAN PROSPECTIVE INVESTIGATION ON DIET, CANCER
AND HEALTH (EPIC)
E
PIC is a multicentre, cohort study with a primary objective to investigate the
relationship between nutritional status, lifestyle, genetic and environmental
factors and the incidence of cancer and other chronic diseases. UNAC is
engaged in several EPIC-related areas of research, leading the working
groups on gastric, oesophageal and pancreatic cancers. In addition, UNAC works in
close collaboration with other EPIC research groups studying lung, prostate, colorectal,
bladder, cervical cancer, breast and other hormone-related cancers. EPIC has identified
more than 90 000 cases of cancer and is one of the largest existing studies of this type
in the world—with data from approximately 500 000 individuals followed for more than
15 years in 10 European countries, including Spain. For more information on the EPIC
Study, please visit: http://epic.iarc.fr/index.php.
GASTRIC CANCER
E
nvironmental factors, helicobacter pylori infection, genetic susceptibility and gastric cancer risk in the European population (EURGAST I and EUR-GAST II). One of UNAC’s main objectives is to advance European and international knowledge in the area of
gastric cancer--the fifth most common malignancy and the third leading cause of cancer death worldwide. Research is still needed
to elucidate the causes of this disease and to identify effective biomarkers for its early detection and prognosis, as well as identify
specific targets for its treatment. EUR-GAST is a case-control study nested within the EPIC cohort, aimed to clarify the role of several
environmental and genetic factors in the process of gastric and oesophageal carcinogenesis. Project activities include evaluation of the
role of environmental factors, such as Helicobacter pylori and EBV infection, diet and circulating levels of nutrients and vitamins, alcohol
consumption and smoking, on gastric cancer risk. The roles of epigenetic and genetic factors are also analysed. Other research lines and
activities include:
• factors and molecular mechanisms involved in the progression of gastric precancerous lesions to gastric cancer
• validation in independent populations and functional characterisation of genetic susceptibility factors
• analysis of factors involved in the progression and response to treatment of the disease
• participation in two international GWAS on gastric cancer
PI: Antonio Agudo
Key Publication: González CA, et al. Helicobacter
pylori infection assessed by ELISA and by
immunoblot and noncardia gastric cancer risk in a
prospective study: the Eurgast-EPIC project. Ann
Oncol 2012;23:1320-4.
CANCER AND DIETARY PATTERNS
T
he role of a Mediterranean dietary. Dietary pattern analysis has become an increasingly important area of research in the study of dietdisease associations. Analysing food consumption as dietary patterns not only offers a new perspective from the traditional ‘single nutrient’
point-of-view, but may provide a more comprehensive approach towards disease treatment and prevention—facilitating translation into
public health guidelines. UNAC’s primary lines of research in this field are the role of a Mediterranean diet and the inflammatory potential
of diet. UNAC researchers are designing a project to investigate circadian clock systems and chronodisruption of diet in order to better understand
the aetiology of obesity and related diseases such as type II diabetes and metabolic syndrome.
DETAILS
T
T
PI: Genevieve Buckland
PI: Paula Jakszyn
he role of a Mediterranean dietary. Adherence to a
traditional Mediterranean diet is associated with significant
reductions in chronic disease-related morbidity and
mortality. UNAC researchers are active in the examination
of the relationship between various Mediterranean dietary patterns
and the risk of gastric and oesophageal cancers. Other areas of
research include adherence to a Mediterranean diet and the risk
of breast cancer and bladder cancer; a healthy lifestyle index
encompassing the Mediterranean diet and gastric cancer; the
Mediterranean diet and risk of myocardial infarction (EPIC-Spain).
he inflammatory potential of diet. Studies have shown
that various factors such as diet, abdominal adiposity
and low levels of physical activity may be the origin of a
phenomenon known as ‘low-grade chronic Inflammation’,
the physiological basis of several chronic diseases and the
development of various tumours. Starting with the Spanish EPIC
cohort, UNAC is working to develop models to estimate the potential
risk of an inflammatory diet and to assess its possible relationship
with the risk of several malignant tumours and mortality.
Key Publication: Buckland G et al. Adherence to the Mediterranean Diet and risk of breast cancer in the European prospective investigation into
cancer and nutrition cohort study. Int J Cancer 2013; 132:2918-27.
PANCREATIC CANCER
I
nvestigation of cancer of the pancreas. Pancreatic cancer is the most lethal of all cancers; with
5-year survival at 5-7%. Currently, most cases of pancreatic cancer are identified well after the
disease has metastasised (spread) to other organs in the body. Other than surgery, which is an
option for about 15% of patients, there are no effective treatments for pancreatic cancer. Thus,
identifying the disease early with the use of non-invasive blood-based biomarkers is an urgent
research priority. Primary prevention is also a research priority; however, complete understanding
regarding the causes of the disease are lacking. UNAC conducts and collaborates on a number
of international epidemiological studies, within the EPIC cohort, and two international consortia–
PanC4 (The Pancreatic Cancer Case-Control Consortium) and PanScan (The Pancreatic Cancer
Cohort Consortium), as well as the following lines of research:
• genetic susceptibility, genome-wide association, and gene-environment interactions
• toxic metals (dietary and environmental) and pancreatic cancer risk in the EPIC cohort
• evaluation of markers of epigenetic dysregulation as biomarkers of early disease detection
• role of common infections
• dietary consumption and pancreatic cancer
• healthy lifestyle and preventing pancreatic cancer
• role of a Mediterranean diet in pancreatic cancer
• hormonal factors and gender differences in pancreatic cancer incidence
PI: Eric Duell
Key Publication: Duell EJ et al. Association between pancreatitis and pancreatic cancer risk in the
international pancreatic cancer case-control consortium (PanC4). Ann Oncol 2012; 23:2964-70.
NUTRITIONAL EPIDEMIOLOGY
N
utritional epidemiology is the study of human health in relation to nutrition. What
started as a small sub-discipline of epidemiology has now grown into a significant
field of public health importance. The EPIC study has collected data on the dietary
habits of more than 500 000 people in 10 European countries; moreover the collection
of detailed data on other lifestyle factors, can be used to correct diet—disease associations for
potential confounding bias. Being one of the largest prospective cohort studies on nutrition,
the EPIC study has detected novel associations and provided considerable evidence for
existing hypotheses. Furthermore, UNAC has made valuable contributions to the field through
its research on the consumption of fruits and vegetables, meat and meat-related components
such as N-nitroso-compounds and endogenous nitrosation, dietary flavonoids and polyphenol
intake.
DETAILS
Key Publication: González CA et al. Meat intake and risk of stomach and esophageal
adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition
(EPIC). J Natl Cancer Inst 2006; 98:345-54.
BIOMARKERS
R
esearch on dietary biomarkers related to cancer and nutrition. In recent decades,
cancer research has used biochemical markers with a focus on: better defining
exposure, improving early detection, refining susceptibility, increasing understanding
of disease aetiology and improving treatment. Although most work nutritional
epidemiology from the EPIC study used data from dietary questionnaires, an increasing amount
of research in the past decade has made use of nutritional biomarkers to assess exposure, as
well as to identify genetically-susceptible individuals at high-risk of cancer. However, evidence
establishing a causal link between biomarkers of specific dietary constituents and cancer is
lacking. UNAC researchers have made valuable contributions in this area. Major findings
include associations of haemoglobin adducts of acrylamide with endometrial and ovarian
cancers; aromatic adducts with gastrointestinal, lung, and breast cancers and; markers of iron
homeostasis with gastric adenocarcinoma, UNAC has also initiated research on the effect of
Bisphenol-A in breast and prostate cancers and in cardiovascular disease as well as research
to identify a biomarker of olive oil. Additional research includes the analysis of the levels of diet
and other lifestyle factors in relation to serum levels of organochlorine pesticides and PCBs,
as well as with the adduct levels of acrylamide and aromatic compounds such as polycyclic
aromatic hydrocarbons.
DETAILS
Key Publication: Fonseca-Nunes A et al. Body iron status and gastric cancer risk in the
EURGAST study. Int J Cancer 2015;137:2904-14.
RESEARCH ON CANCER SURVIVORSHIP
P
revention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention.
There is growing interest regarding the potential role of nutrition in the prognosis and progression of disease
in cancer survivors; particularly for cancer that are causally related to diet. Recent advances in breast cancer
treatment and improved screening have resulted in an increased number of survivors. However, since
recurrences are still a relatively common event, there is a critical need to investigate modifiable factors that could
impact disease recurrence and long-term prognosis. There is substantial evidence from observational studies showing
that weight management, increased physical activity and dietary modification may be effective methods to reduce
recurrences and improve survival. To confirm the role of these lifestyle factors on breast cancer, further research is
needed to establish specific lifestyle recommendations. UNAC coordinates a multicentre, randomised clinical trial
(PREDICOP) aimed to assess the effect of a lifestyle intervention combining weight control, diet and physical activity
on the risk of relapse among breast cancer patients, as well as the effect of the intervention on survival and quality
of life. This trial will include about 200 women aged up to 75 years, diagnosed with non-metastatic breast cancer
(stage I, II, IIIA). Participants will be assigned to either an intervention or a control group, and followed for five years.
Patients in the intervention group will be involved in a lifestyle programme with two components. The dietary part will
aim to achieve a calorie reduction while maintaining nutritional quality; the physical activity part will include supervised
sessions of moderate intensity.
PI: Antonio Agudo; Project Managers: Noemie Travier, Genevieve Buckland
Key Publication: Travier N et al. Effects of an 18-week exercise programme started early during breast cancer treatment:
a randomized controlled trial. BMC Med 2015; 13:121.
OTHER ACTIVITIES
U
NAC researchers have participated several EPIC-related lines of research investigating environmental and
reproductive factors as well as molecular and genetic epidemiology, including one area of investigation with
particular relevance: the impact of tobacco smoking. Other interests include factors related with overall health
and mortality and factors related to obesity and weight change (the PANACEA study). UNAC researchers are
also active in several international consortia, including ARCAGE / INHANCE, Panc4 and ILCCO.
Key Publication: Agudo A et al. Impact of cigarette smoking on cancer risk in the European prospective investigation
into cancer and nutrition study. J Clin Oncol 2012; 30:4550-7.
Meet PREC’s Team
INFECTIONS AND CANCER UNIT
NUTRITION AND CANCER UNIT
RESEARCH SUPPORT
Leadership Team
Leadership Team
Administrative Team
Silvia de Sanjosé
Programme Director
Silvia de Sanjosé
Programme Director
Cristina Rajo
Head of Research Project Management
Xavier Castellsagué
Infections and Cancer, Head of Unit
Antonio Agudo
Nutrition and Cancer, Head of Unit
Ángela Expósito
Administrative Assistant – Nutrition and Cancer Unit
F. Xavier Bosch
Senior Consultant to PREC
Ion Espuña
Administrative Assistant – Infections and Cancer Unit
Scientist Group
Scientist Group
Ginesa Albero, Research Assistant
Eric J. Duell, Researcher
Marta Aldea, Research Assistant
Nadia García, Technician
Laia Alemany, Researcher
Carlos A González, Emeritus Researcher
Leslie Barrionuevo, Research Assistant
Paula Jakszyn, Researcher and Associate Professor
Yolanda Benavente, Research Assistant
Leila Luján, Research Assistant and Associate Professor
Maria Brotons, Researcher
Mireia Obón, PhD Student
Laia Bruni, Researcher
Núria Sala, Researcher
Vanesa Camon, Technician
Noemie Travier, Research Assistant
Delphine Casabonne, Researcher
Raul Zamora, Researcher
Omar Clavero, Researcher
Laura Costas, Researcher
Mireia Diaz, Researcher and Associate Professor
Ana Esteban, Technician
Marta Félez, PhD Student
Yolanda Florencia, Technician
Nati Patón
Administrative Assistant – Infections and Cancer Unit
IT Team
Jesus Muñoz
IT Manager
Xesco Alarcón
IT Assistant
E-oncología Team
Assumpta Company
Academic Director
Natalia Casal
Learning Technician
Olga Guillen
Learning Technician
Mireia Montserrat
Learning Technician
Raquel Ibáñez, Research Assistant
Marisa Mena, Researcher
Beatriz Mengual-Chuliá, PhD Student
Sara Nicolàs, PhD Student
Ville Nikolai, Researcher
Beatriz Quirós, Technician
Vanesa Rodríguez, PhD Student
Esther Roura, Research Assistant
Beatriz Serrano, Research Assistant
Miren Taberna, Researcher
Sara Tous, Research Assistant
Marleny Vergara, Technician
CONTACT US
Cancer Epidemiology Research Programme
Institut Català d’Oncologia (ICO)
Av. Gran Via de l’Hospitalet 199-203
08908 L’Hospitalet de Llobregat (Barcelona)
Spain
Tel.: +34 932 607 812 • +34 932 607 401
Fax: +34 932 607 787
[email protected]
http://icoepi.net
http://ico.gencat.cat/en/